-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $185 Price Target

Benzinga·10/02/2026 11:29:20
语音播报
HC Wainwright & Co. analyst Arthur He reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $185 price target.